1. Home
  2. LTRN vs HXHX Comparison

LTRN vs HXHX Comparison

Compare LTRN & HXHX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LTRN
  • HXHX
  • Stock Information
  • Founded
  • LTRN 2013
  • HXHX 2003
  • Country
  • LTRN United States
  • HXHX China
  • Employees
  • LTRN N/A
  • HXHX N/A
  • Industry
  • LTRN Biotechnology: Pharmaceutical Preparations
  • HXHX Trucking Freight/Courier Services
  • Sector
  • LTRN Health Care
  • HXHX Industrials
  • Exchange
  • LTRN Nasdaq
  • HXHX Nasdaq
  • Market Cap
  • LTRN 36.1M
  • HXHX 36.9M
  • IPO Year
  • LTRN 2020
  • HXHX 2025
  • Fundamental
  • Price
  • LTRN $3.05
  • HXHX $1.67
  • Analyst Decision
  • LTRN Strong Buy
  • HXHX
  • Analyst Count
  • LTRN 1
  • HXHX 0
  • Target Price
  • LTRN $25.00
  • HXHX N/A
  • AVG Volume (30 Days)
  • LTRN 71.9K
  • HXHX 171.6K
  • Earning Date
  • LTRN 05-15-2025
  • HXHX 01-01-0001
  • Dividend Yield
  • LTRN N/A
  • HXHX N/A
  • EPS Growth
  • LTRN N/A
  • HXHX N/A
  • EPS
  • LTRN N/A
  • HXHX 0.26
  • Revenue
  • LTRN N/A
  • HXHX $25,571,810.00
  • Revenue This Year
  • LTRN N/A
  • HXHX N/A
  • Revenue Next Year
  • LTRN N/A
  • HXHX N/A
  • P/E Ratio
  • LTRN N/A
  • HXHX $6.31
  • Revenue Growth
  • LTRN N/A
  • HXHX N/A
  • 52 Week Low
  • LTRN $2.55
  • HXHX $1.29
  • 52 Week High
  • LTRN $6.40
  • HXHX $6.29
  • Technical
  • Relative Strength Index (RSI)
  • LTRN 40.80
  • HXHX N/A
  • Support Level
  • LTRN $2.85
  • HXHX N/A
  • Resistance Level
  • LTRN $3.23
  • HXHX N/A
  • Average True Range (ATR)
  • LTRN 0.38
  • HXHX 0.00
  • MACD
  • LTRN -0.09
  • HXHX 0.00
  • Stochastic Oscillator
  • LTRN 12.41
  • HXHX 0.00

About LTRN Lantern Pharma Inc.

Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.

Share on Social Networks: